Study of pemvidutide for liver scarring from MASH
Part of Digestive system, Hormones & metabolism clinical trials.
This study tests an investigational medicine called pemvidutide to see if it can reduce liver scarring in people with MASH (a liver condition linked to excess weight and metabolic issues). It may help improve liver health and potentially slow or reverse the condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have MASH with moderate liver scarring (stage F2 or F3), confirmed by a liver biopsy or by noninvasive tests.
- Your weight is stable (no major changes in the last 3 months) and your body mass index (BMI) is 25 or higher (or 23 if Asian).
- You have type 2 diabetes or at least two signs of metabolic syndrome (like high blood pressure, high blood sugar, or abnormal cholesterol).
- You are willing to have one or more liver biopsies as part of the study.
- You do not have cirrhosis or other serious liver diseases, and your liver function tests are within safe limits.
- Your diabetes (if you have it) is not uncontrolled, and you do not have persistent high blood sugar.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called IBI362 for people with MASH, a type of fatty liver disease that has caused liver scarring (stage F2 or F3). The study aims to see if the drug can improve the liver's health.
This trial tests an investigational drug called survodutide for people with NASH or MASH, a type of fatty liver disease that also has liver scarring (moderate or advanced fibrosis). The goal is to see if the drug can improve the condition.
This study tests an investigational drug called ALN-CIDEB for people with MASH, a liver condition linked to metabolic issues, that has caused moderate liver scarring. The goal is to see if the drug can reduce liver damage and improve liver health.
This trial tests a new medication called UBT251 for people with MASH, a type of liver disease linked to weight and metabolism. It aims to see if the medicine can reduce liver damage and scarring.
This trial tests two new injections (HRS-4729 and HRS-9531) for people with MASH, a type of fatty liver disease. The study aims to see if these drugs can help reduce liver fat and improve liver health.
This Phase 2 study tests a gene-silencing treatment to improve chronic liver disease called MASH, especially in people with certain genetic risk. You may be eligible if you have MASH with moderate-to-advanced scarring and specific test results, and if other liver causes and recent substance/alcohol issues don’t apply.
Hear when a new Metabolic Dysfunction-Associated Steatohepatitis (MASH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.